- Home
- BLRX vs FGEN Comparison
BLRX vs FGEN Comparison
Compare BLRX & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- FGEN
- Stock Information
- Founded
- BLRX 2003
- FGEN 1993
- Country
- BLRX Israel
- FGEN United States
- Employees
- BLRX N/A
- FGEN N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- FGEN Health Care
- Exchange
- BLRX Nasdaq
- FGEN Nasdaq
- Market Cap
- BLRX 36.0M
- FGEN 34.5M
- IPO Year
- BLRX 2011
- FGEN 2014
- Fundamental
- Price
- BLRX $0.20
- FGEN $0.36
- Analyst Decision
- BLRX Strong Buy
- FGEN
- Analyst Count
- BLRX 2
- FGEN 0
- Target Price
- BLRX $5.50
- FGEN N/A
- AVG Volume (30 Days)
- BLRX 2.2M
- FGEN 898.0K
- Earning Date
- BLRX 11-25-2024
- FGEN 11-12-2024
- Dividend Yield
- BLRX N/A
- FGEN N/A
- EPS Growth
- BLRX N/A
- FGEN N/A
- EPS
- BLRX N/A
- FGEN N/A
- Revenue
- BLRX $21,991,000.00
- FGEN $180,015,000.00
- Revenue This Year
- BLRX N/A
- FGEN $19.67
- Revenue Next Year
- BLRX N/A
- FGEN N/A
- P/E Ratio
- BLRX N/A
- FGEN N/A
- Revenue Growth
- BLRX N/A
- FGEN 16.15
- 52 Week Low
- BLRX $0.19
- FGEN $0.18
- 52 Week High
- BLRX $1.70
- FGEN $2.93
- Technical
- Relative Strength Index (RSI)
- BLRX 24.20
- FGEN 45.24
- Support Level
- BLRX $0.23
- FGEN $0.31
- Resistance Level
- BLRX $0.56
- FGEN $0.37
- Average True Range (ATR)
- BLRX 0.03
- FGEN 0.03
- MACD
- BLRX -0.00
- FGEN -0.01
- Stochastic Oscillator
- BLRX 7.26
- FGEN 25.66
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.